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from presentation was considered a good
result, and longer healing times a poor result.
Logistic regression was used to predict
a good/poor result, the primary outcome,
using log2-transformed MIC as a covariate.
The regression model was analysed using
Pearson’s goodness of ﬁt. A Fisher ’s exact test
was used to correlate genus (Aspergillus vs
Fusarium) to good/poor result. All analyses
were performed using STATA 9.2.
RESULTS
The baseline characteristics and MICs of 54
patients with fungal corneal ulcers are
described in table 1.
A lower MIC was signiﬁcantly associated
with a good outcome, as was Fusarium species
(as opposed to Aspergillus species) (table 2).
When restricted to a subgroup of organ-
isms, for example Fusarium cases, the
relationship between MIC and clinical
outcome was similar in magnitude, but no
longer statistically signiﬁcant (OR¼0.51,
95% CI 0.12 to 2.05, p¼0.34). In addition,
when restricted to only Aspergillus cases, the
relationship was neither signiﬁcant nor
similar in magnitude (OR¼1.37, 95% CI 0.39
to 4.88, p¼0.63).
COMMENT
Many factors contribute to the success or
failure of fungal keratitis management,
including ulcer size, ulcer location, organism,
penetration of antimicrobial agent and
susceptibility of the organism to treatment.
In bacterial keratitis, studies suggest that
susceptibility of the organism to the agent in
vitro correlates with outcome.6 7 It remains
unclear whether susceptibility correlates
with outcome in fungal keratitis.8 9 In
systemic fungal disease, researchers suggest
that the role of susceptibility testing may be
similar to that of bacterial susceptibility
testing, where approximately 90% of
susceptible cases and 60% of resistant cases
respond to therapy.1 Antifungal suscepti-
bility testing is associated with outcome in
mucosal candidiasis and candidaemia, and
antifungal susceptibilities inﬂuence treat-
ment recommendations.10
In fungal keratitis, in vitro susceptibility
did correlate with outcome. A twofold
increase in MIC was associated with a 47%
reduction in the odds of healing. In addition,
the organism is associated with outcome.
Since only 54 of 90 cases with completed
susceptibility testing had clinical data avail-
able, the study had limited generalisability.
Further prospective studies would be neces-
sary to assess whether MIC provides infor-
mation useful to the clinician once the
organism species has been identiﬁed, as well
as the effect of other covariates such as
toxicity, prior medications, age and sex.
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Counselling for people with sight
loss in the UK: the need for
provision and the need for
evidence
For adults of any age the diagnosis of a visual
impairment can be traumatic, and timely
referral to informal peer support and/or
Table 1 Fungal organisms isolated from retrospective review of corneal ulcers from MarcheJune
2004 (n¼54)*
Organisms n (%) MIC50 (mg/ml) MIC90 (mg/ml) MIC range (mg/ml)
Aspergillus species 24 (44) 32 64 8e64
Aspergillus flavus 18 (33) 32 64 16e64
Aspergillus niger 2 (4) e e 8e32
Aspergillus terreus 3 (6) e e 8e32
Aspergillus fumigatus 1 (2) e e 8e8
Fusarium species 23 (43) 8 16 4e16
Unidentified hyaline species 3 (6) e e 8e64
Acremonium species 1 (2) e e 4
Bipolaris species 1 (2) e e 32
Curvularia species 2 (4) e e 4
*For the complete baseline characteristics and MICs for all 98 isolates, see previously published data.3
MIC, minimum inhibitory concentration.
Table 2 Univariate analysis predicting healing at 3 weeks in fungal corneal ulcers (n¼54)
Covariate OR (95% CI) p Value
MIC (mg/ml) to natamycin 0.53 (0.32 to 0.86)*y 0.01
Fusarium (vs Aspergillus species) 4.94 (1.17 to 22.3) 0.01
*OR per twofold dilution in MIC.
yPearson’s goodness of fit: p¼0.33.
MIC, minimum inhibitory concentration.
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professional counselling may be both bene-
ﬁcial and appropriate. It is estimated that
45/113 (40%) of UK voluntary organisations
for people with sight loss provide profes-
sional counselling (n¼17) or ‘informal
support’ (n¼28), such as peer support groups,
telephone helplines and befriending.1
However, what is the evidence that these
services help people adjust emotionally to
their acquired vision loss and the conse-
quences that ﬂow from this?
During the spring/summer of 2008, we
conducted a follow-up to the scoping survey
reported earlier1 to assess the evidence for
effectiveness of professional counselling
services for people with acquired sight loss.We
contacted the 17 counselling services previ-
ously identiﬁed by Rees1 and further services
via Vision 2020 UK, the National Association
of Local Societies for Visually Impaired People,
the Visual Impairment Network for Counsel-
ling and Emotional Support, and specialist
ophthalmic nurses via the Royal College of
Nursing. To evaluate the evidence for coun-
selling services we requested the documenta-
tion used to support their development and
copies of any evaluation reports.
We identiﬁed 28 services providing
professional counselling in the UK for people
with sight loss, 25 of which provided
a service to a speciﬁc geographical area and
three nationally by telephone. Counselling
was rarely provided through the NHS or via
social services (8/28), and whilst free tele-
phone-based counselling was available across
the UK, the provision of free face-to-face
counselling was patchy.
Six organisations initiated their services in
response to a range of policy and research
reports: a policy document outlining the
provision of social services for visually
impaired adults (n¼1)2 plus a low vision
consensus forum document (n¼1),3
a research report by the Royal National
Institute of Blind People (RNIB) (n¼2),4 and
an evaluation report by the RNIB showing
promise for a face-to-face formal counselling
service pilot service (n¼2).5
Of the 28 counselling services, three were
in the process of being evaluated, 11 had not
been evaluated, 11 had collected client
satisfaction data that would need to be
updated and enhanced with validated scales,
and three provided evaluation reports. Two
of the three reports were of cross-sectional
evaluations using client satisfaction data,
but one report found that 100% of clients on
completion of face-to-face counselling had
reliably and signiﬁcantly improved in
emotional well-being, including a 41%
reduction in mild risk of suicide. This pilot
could be built upon with trials using more
stringent controls of confounding variables
and longer-term follow-up.
Our scoping survey was limited in that
some services operating in the UK may not
have been captured by our recruitment
strategy. It is unclear whether these services
provided formal counselling as 4/28 services
were not provided by qualiﬁed counsellors,
16/28 organisations could not detail the
training of their counsellors, and 11/28 could
not characterise the type of counselling
provided (eg humanistic, psychodynamic,
etc). Our ﬁndings suggest that there is ineq-
uity in the provision of free face-to-face
counselling to people with vision loss in the
UK and that there has been little systematic
evaluation of the counselling services avail-
able. The RNIB’s pilot counselling services
show promise,6 but their evaluations have
yet to recruit control groups or assess long-
term outcomes. We call upon researchers to
evaluate emotional support services for
people with sight loss to provide an evidence-
base for their effectiveness in enhancing
psychosocial well-being and to inform how
these services can be improved. With this
evidence voluntary organisations would
receive greater recognition and funding for
their emotional support services, thereby
enhancing the quality of life of people with
vision loss.
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VSX2 in microphthalmia: a novel
splice site mutation producing
a severe microphthalmia
phenotype
Microphthalmia shows great genetic and
clinical heterogeneity, whether as part of
a syndrome or an isolated ocular phenotype.
Chromosomal or single-gene disorders and
teratogens may all cause microphthalmia.
Associated syndromic features include
cardiac problems, clefting, microcephaly and
learning disabilities.1 Microphthalmia is
frequently bilateral, but commonly asym-
metrical in severity.
Homozygous mutations in VSX2/CHX10
have been demonstrated in human and
murine microphthalmia.2 3 VSX2 is thought
to act principally as a repressor of transcrip-
tion, particularly of the genes encoding
cyclin-dependent kinase inhibitor (p27kip1)
and microphthalmia transcription factor
(MITF).4 These repressive roles enable cell
proliferation by preventing retinal progenitor
cells from exiting the cell cycle, and by
maintaining neuroretinal cell identity. Loss of
these functions therefore causes failures in
eye development. Other genes implicated in
microphthalmia include SOX2, PAX6, sonic
hedgehog (SHH), RAX, OTX2, CRYBA and
FOXE3.1 Additional loci with no gene iden-
tiﬁed include 15q12eq15, 14q32 and
Xq27eq28.1
Our patient has healthy ﬁrst-cousin
Turkish parents with no ocular anomalies,
and an unaffected brother. Her very small
eyes were noted at birth, but no other
congenital anomalies. Her karyotype
demonstrated 46, XX. Cranial MRI (see
ﬁgure 1) conﬁrmed severe microphthalmia
and small optic nerves. Growth and devel-
opment, given complete absence of vision,
have progressed normally to her current age
of 3.5 years. Neonatally, the right vestigial
scleralised globe had no discernible anterior or
posterior segment structures. The micro-
phthalmic left globe had a clear cornea and
formed anterior chamber but abnormally
vascularised iris, with inferior colobomatous
malformation. Light perception was absent
on the right, and possibly present on the left.
At age 3 years, the left eye remained severely
microphthalmic (axial length 12.2 mm) with
no useful vision. The cornea remained clear,
intraocular pressure was normal (10 mmHg),
but leucocoria suggested a retrolental plaque.
B-scan ultrasound revealed total retinal
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